Onco Actu - Spécial AACR 2

Lire aussi l'autre billet du jour

	5.9 AACR
American Association for Cancer Research Inaugurates New Leadership at 2015 Annual Meeting [AACR] The American Association for Cancer Research (AACR) welcomes José Baselga, MD, PhD, as president of the organization for 2015-2016.
New SU2C-OCRF-OCNA-NOCC Ovarian Cancer Dream Team Announced; $6 Million Grant Over 3 Years Will Focus on DNA Repair Therapies [AACR] “We hope to extend the use of PARP inhibitors to many other patients and find combinations with other drugs that will be effective against ovarian cancer.”
	5.9.1 AACR - sein
Adding the PI3K Inhibitor BYL719 to Letrozole Was Safe, With Early Signs of Activity Against Metastatic ER-positive Breast Cancer [AACR] Analysis of tumor samples from the patients showed that 61 percent had mutations in the PIK3CA gene. Mayer noted that the BYL719 and letrozole combination had clinical activity in both patients with and without these mutations, but a higher proportion of the clinical benefit was seen in patients with PIK3CA mutations.
Dual mTOR Inhibitor-Fulvestrant Combo Feasible, With Clinical Benefit for Advanced Breast Cancer Patients [AACR] Patel cautioned that this is a small phase I study that is not statistically powered to determine which schedule has the best efficacy. This is being explored further in a phase II study called MANTA, which compares fulvestrant with or without one of the two schedules of AZD2014 as well as fulvestrant with another mTOR inhibitor, everolimus.
Black Women Found to Have Denser Breast Tissue Than White Women [AACR] “Our findings are using a new, quantitative and, perhaps, more reliable way to measure breast density,” McCarthy said. “Our next step will be to see how quantitative density measures and other imaging biomarkers are associated with cancer risk, cancer subtype, and stage of diagnosis by race.”
New Antibody-Drug Conjugate Shows Early Promise for Patients With Metastatic HER2-positive Breast Cancer [AACR] MM-302 is an antibody-drug conjugate composed of a HER2-targeted antibody linked to the cytotoxic chemotherapy liposomal doxorubicin. The HER2 antibody delivers the liposomal doxorubicin to HER2-positive breast cancer cells.
Investigational ER Degrader Safe, With Early Signs of Antitumor Activity Against Advanced ER-positive Breast Cancer [AACR] Dickler explained that GDC-0810 is a selective ER degrader and that it works in a number of ways to prevent estrogen fueling tumor growth. She said that it not only targets the ER, like the antiestrogen tamoxifen, but also causes ER degradation.
Extended Overnight Fasting May Lead to Reduced Breast Cancer Risk [AACR] “This finding is relevant to cancer research because people who have poor glucose control are more likely to develop certain types of cancer, and it is hypothesized that high concentrations of circulating glucose may fuel cancer growth and progression."
Investigational PD-L1–targeted Immunotherapy Safe for Patients With Triple-negative Breast Cancer, Effective in Some [AACR] “The latest analysis of our data revealed a 24-week progression-free survival rate of 27 percent, with an objective response rate of 19 percent, and three of four responses are ongoing.”
Fasting at night lowers risk of breast cancer and diabetes [The Telegraph] For every three hours of extra fasting at night women were 20 per cent less likely to have hyperglycemia - or high blood sugar - a known risk factor for breast cancer and diabetes.
	5.9.1.1 AACR - sein (observation)
U.S. Breast Cancer Cases Expected to Increase by as Much as 50 Percent by 2030 [AACR] “These distinct patterns within the overall breast cancer picture highlight key research opportunities that could inform smarter screening and kinder, gentler, and more effective treatment.”
Breast Cancer Cases To Increase 50% By 2030. Don't Panic. [Forbes] A lot of the cases in Rosenberg’s presentation – about half the increase – is in what is called carcinoma in situ. These are smaller, earlier cancers, and some experts argue that they shouldn’t be considered cancers at all.
Breast cancer cases in U.S. projected to rise as much as 50% by 2030 [LA Times] The researchers also predicted that the age distribution of women with new breast cancers would change by 2030, with the percentage of new cases occurring in women ages 70-84 expected to increase from 24% to 35% and that in women ages 50-69 was expected to fall from 55% to 44%.
	5.9.3 AACR - mélanome
First Randomized Study Evaluating Opdivo (nivolumab)+Yervoy (ipilimumab) Regimen Demonstrates Superior Efficacy Versus Yervoy Alone in Patients with Previously Untreated Advanced Melanoma |[BMS] “The CheckMate -069 results reinforce our belief that the future lies in the combination of Immuno-Oncology agents, including Opdivo and Yervoy, that can leverage the immune system in order to offer cancer patients options with greater efficacy beyond current treatment approaches.”
Phase II Trial of Ipilimumab-Nivolumab Combo Shows Promise in Advanced Melanoma [AACR] In this phase II, double-blind trial, 142 patients with advanced melanoma who had not received prior therapy were enrolled. Of these patients, 109 had the normal form of the gene BRAF in their tumors and 33 had BRAF V600 mutations.
Immune System Drugs Melt Tumors In New Study, Leading A Cancer Revolution [Forbes] The results show that the anonymous woman’s case was anything but a fluke, as the combination of the two drugs had unprecedented cancer-fighting potency, but also caused toxicity: 50% of patients had side effects that were severe or life-threatening.
Bristol-Myers immunotherapy combo promising in melanoma: study [Reuters] The overall response rate, defined as tumors that shrank by at least 30 percent, was 61 percent for the 72 patients who received the combination versus 11 percent among the 27 who got Yervoy alone.
	5.9.4 AACR - poumon
New SU2C-American Cancer Society Lung Cancer Dream Team Announced [AACR] $20 million project will combine targeted therapies and immunotherapy; Bristol-Myers Squibb contributing $5 million to SU2C to support team.
'Liquid biopsy' picks up cancer biomarkers in blood, study finds [LA Times] The results also lend further support to the idea that, in many cases, non-invasive blood tests may be able to detect cancer biomarkers as effectively as traditional biopsies.
	5.9.5 AACR - CAR-T
Novartis solid tumor 'CAR T cell' still holds promise: researcher [Reuters] Penn oncologist Janos Tanyi, who helped lead the Phase 1 study, said the trial met its primary goal of safety, with no major adverse events seen after 28 days of treatment. But neither did any of the patients' tumors shrink.
	5.9.6 AACR - divers
Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 [Lilly] Diverse pipeline compounds target key cancer pathways.
Foundation Medicine and Collaborators to Present New Data in 12 Oral and Poster Presentations at the AACR Annual Meeting [Foundation Medicine] The data to be presented at AACR add to a growing body of evidence revealing the critical distinctions between hotspot-based testing, which analyses a single or small set of genes or a specific region in such genes, and validated comprehensive genomic profiles, which analyze the entire coding regions of cancer genes and detect all four classes of genomic alterations.
Real-world Targeted Treatment Based on Whole Genome Sequencing Difficult in Pancreatic Cancer [AACR] “Our data highlight just how difficult it is to do this sort of trial in a poor-prognosis cancer like pancreatic cancer."
Time Bungles Precision Medicine [The Scientist] Personalized pancreatic cancer therapies based on tumor genomics may take too long to prepare to be helpful, according to a small clinical trial.